We are proud to inform you that our friends and cooperation partner from the German cancer research center (DKFZ) published the first study about the application of our Oxygen-17 gas with participants with glioma – Quantitative Dynamic Oxygen 17 MRI at 7.0 T for the Cerebral Oxygen Metabolism in Glioma – in the medical journal Radiology.
As part of our strategy to streamline our corporate structure and internal procedures, the management has decided to merge the activities of NUKEM Isotopes Imaging GmbH with those of NUKEM Isotopes GmbH. On this occasion, the company was merged with retroactive effect to 01.01.2019 on the NUKEM Isotopes GmbH. This step has already been certified by the notary and will be registered with the commercial register in a timely manner. We are confident that this step will further improve the service to our customers and suppliers and will contribute to more efficient fulfillment of the needs of our client orders. As a result of this operational change, customer orders for isotopes which find their application in medical technology, e.g. Oxygen-17 or Xenon-129 are again accepted directly by NUKEM Isotopes GmbH.
If you need more information on this topic, please do not hesitate to contact us anytime at email@example.com. Of course you are also welcome to contact your direct contacts.
Alzenau, Germany – It is with a mix of sadness and gratitude that the Board of Directors announces Jürgen Laucht‘s departure as Managing Director of NUKEM Isotopes GmbH.
Since 2011, Jürgen has played a critical role in the development and success of the organization and while we will miss him, we wish him the best of luck in his new challenges.
Mr. Wilhelm Plumpe will continue to serve as the companies Chief Executive Officer, while Tilo Gläser (Chief Operating Officer) and Michael Kievel (Chief Sales Officer) will take care for the operations and customer services at NUKEM Isotopes. Together with Ulf Jeschke (Chief Financial Officer) it is the companies’ priority to maintaining a stable and effective organization structure.
Again, we cannot thank Jürgen enough for the dedication, passion and enthusiasm he has given NUKEM Isotopes GmbH over the past years. Even though he decided to retire after so many years in the industry we are glad he will continue being a part of the family. Jürgen will join the advisory broad of NUKEM Isotopes.
Alzenau, Germany – NUKEM Isotopes GmbH is proud to announce and welcome Ulf Jeschke as the company’s Chief Financial Officer (CFO). Ulf will be responsible for Financial Services and Controlling at the Company and its subsidiary and will lead the bookkeeping team. During his successful career in an auditing company and in the commodity trading industry, he has gained experience as a leader of the financial group.
The whole team at NUKEM Isotopes is very excited to welcome Ulf to the NUKEM Isotopes family. He brings to us and our clients tremendous experience, knowledge and is respected throughout the industry for his honesty, integrity and accomplishments. He truly shares our vision, passion and above all, our commitment to satisfying our customers’ needs.
We have moved! In the course of our general expansion strategy, the company has decided to build a new, state of the art office building, in order to fulfil future needs. Now, after almost 12 months of intense planning- and construction work, we are very proud to announce the completion of this challenging project. With almost 1,000 m² of bright, modern offices, combined with functional storage- and packing space, we are confident, we have established a good environment for our employees in order to ensure high quality services for our valued customers.
In light of this move, our address, as well as phone numbers have changed. Our new address can be found here and our new contact information (our email addresses stay the same) can be found here (phone numbers will be updated soon).
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH have successfully completed its re-certification audits, performed by BSI Group Deutschland GmbH, for the new ISO 9001:2015 quality management standard for NUKEM’s activities in trading isotopes and trading isotops for medical purposes.
As supporter for supplying high enriched Oxygen-17 (70at%) gas, we are proud to announce that the manuscript “Reproducibility of CMRO2 Determination using Dynamic 17O MRI”, submitted by the German Cancer Research Center (DKFZ) and the University of Erlangen, was accepted for publication by the journal Magnetic Resonance in Medicine. The manuscript will probably be online by end October 2017.
NUKEM Isotopes GmbH successfully completed the REACH-Registration for Li-7OH*H2O. This Registration entitles us to import more than 1t/a of Li-7OH*H2O into the European Union also after May 31st, 2018. Thus, we are perfectly prepared to cover the future Li-7 demand of our customers.
NUKEM Isotopes Imaging GmbH successfully participated at this year’s ISMRM in Honolulu. We thank all visitors for stopping by at our booth.
In cooperation with the University of Freiburg, NUKEM Isotopes Imaging GmbH carried out experiments with enriched Oxygen-17 in the form of D-Glucose. Now we are pleased to announce that the University of Freiburg got the manuscript accepted by the journal NMR in Biomedicine.
In cooperation with the University of Heidelberg and the Florida State University, NUKEM Isotopes Imaging GmbH carried out experiments to verify a new technique for detecting brain tumors with enriched Oxygen-17 in the form of D-Glucose.
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH have successfully completed its surveillance audit, performed by BSI Group Deutschland GmbH. This audit has proven both companies operates a Quality Management System which complies with the requirements of ISO 9001:2008 for trading isotopes and trading isotops for medical purposes.
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH launched their new website.
NUKEM Isotopes GmbH has successfully completed its re-qualification audit, performed by NUPIC member group. This audit has proven NUKEM’s management system in accordance to 10CFR50 App.B and 10CFR21. NUPIC audit team consists of professional auditior from Ameren UE, Vattenfall Ringhals Kärnkraftverk and Arizona Public Service Electric Company (APS).
NUKEM Isotopes GmbH decides to participate in Polarean, Inc. a pioneer in hyperpolarized gas technology. This stragegic decision enables NUKEM Isotopes to supply enriched Xenon-129 for lung imaging in MRT.
NUKEM Isotopes GmbH establishes reliable partnerships with gas manufacturers for the production of highly pure noble gases.